Towards Healthcare
Hematologic Malignancies Treatment Market Expands USD 72.49 Billion in 2025

Hematologic Malignancies Treatment Market 2025 Overview Leukemia Leads, Lymphoma Grows Fastest, BTK Inhibitors Rise

Projections indicate that, the global hematologic malignancies treatment market increased from USD 67.32 billion in 2024 to USD 139.13 billion by 2034, experiencing a CAGR of 7.61% over the next 10 years.The global rise in the elderly population, who are more prone to blood cancers, is fueling the growth of the market.  

Content

  • Last Updated: 01 November 2025
  • Report Covered: [Revenue + Volume]
  • Historical Year: 2021-2023
  • Base Year: 2024
  • Estimated Years: 2025-2034

About The Author

Deepa Pandey is a focused and detail-oriented market research professional with growing expertise in the healthcare sector, delivering high-quality insights across therapeutic areas, diagnostics, biotechnology, and healthcare services.

She began her research career at Precedence Research, where she contributed to a wide range of healthcare industry studies, helping build a strong foundation in market intelligence and strategic research. Currently, Deepa plays a critical role at Towards Healthcare, while also extending her research capabilities across Statifacts, supporting cross-industry intelligence initiatives with a focus on healthcare.

Her ability to distill complexity into clarity has made her a trusted contributor to both internal teams and external clients across the healthcare value chain. By combining professionalism with an evolving depth in healthcare research, Deepa consistently adds value to projects that demand critical thinking, market precision, and industry-specific knowledge. Her contributions help organizations navigate the complexities of regulated markets and make data-backed growth decisions.

Talk to us
FAQ's

As of 2024, the global hematologic malignancies treatment market is valued at USD 67.32 billion. It is projected to reach USD 72.49 billion in 2025 and expand to USD 139.13 billion by 2034, growing at a CAGR of 7.61%.

Key growth drivers include rising global prevalence of blood cancers, increasing awareness and early diagnosis, advancements in targeted therapies and immunotherapies, supportive regulatory frameworks, growing clinical trials, and increased healthcare spending.

Common treatments include chemotherapy, radiation therapy, targeted therapy (e.g., tyrosine kinase inhibitors), immunotherapy (e.g., CAR-T cells, monoclonal antibodies), and stem cell transplantation. The choice of treatment depends on cancer type, stage, patient age, and overall health.

NIH, Leukemia & Lymphoma Society (LLS) (LLS), Blood Cancer Alliance, IABCD- Indian Association of Blood Cancer and Allied Diseases, US FDA, and GOV.UK, among others.
Any Questions